{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'Inc., agrees that before it publishes any results of the trial, it shall provide the Investigator with at', 'least 30 days for review of the pre-publication manuscript prior to the submission of the', 'manuscript to the publisher.', 'Stealth BioTherapeutics Inc.', 'CONFIDENTIAL', '79']['SPIMM-301 Version 4.0', '15 June 2018', '13.', 'REFERENCES', 'Chicco AJ, Sparagna GC. Role of cardiolipin alterations in mitochondrial dysfunction and', 'disease. American Journal of Physiology-Cell Physiology. 2007 Jan 1;292(1):C33-44.', 'Chinnery PF. Mitochondrial disorders overview. In: Pagon RA, Adam MP, Ardinger HH, et al.', '(eds). GeneReviews. University of Washington: Seattle, WA, 1993-2014.', 'Davis RL, Liang C, Edema-Hildebrand F, et al. Fibroblast growth factor 21 is a sensitive', 'biomarker of mitochondrial disease. Neurology 2013;81:1819-1826.', 'DiMauro S, Eric A. Schon. Mitochondrial respiratory-chain diseases. New England Journal of', 'Medicine. 2003. 348; 26: 2656-2668.', 'DiMauro S, Hirano M, Schon E. Approaches to the treatment of mitochondrial disease. Muscle', 'Nerve. 2006 Sep;34(3):265-83.', 'DiMauro S. Mitochondrial diseases. Biochimica et Biophysica Acta. 2004. 1658; 80 - 88', 'Fry M, Green DE. Cardiolipin requirement for electron transfer in complex I and III of the', 'mitochondrial respiratory chain. Journal of Biological Chemistry. 1981 Feb 25;256(4): 1874-80.', 'Fujita Y, Ito M, Kojima T, et al. GDF15 is a novel biomarker to evaluate efficacy of pyruvate', 'therapy for mitochondrial diseases. Mitochondrion 2015;20:34-42', 'Gorman G, Schaefer AM, Ng Y, et al. Prevalence of nuclear and mitochondrial DNA mutations', 'related to adult mitochondrial disease. Annals of Neurology. 2015;77(5):753-759', 'doi:10.1002/ana.24362.', 'Haas RH, Parikh S, Falk MJ, Saneto RP, Wolf NI, Darin N, et al: Mitochondrial Medicine', \"Society's Committee on Diagnosis. The in-depth evaluation of suspected mitochondrial disease.\", 'Mol Genet Metab. 2008 May;94(1):16-37.', 'Karaa A, Krieger J, Holbert A, Grier J, Thompson JL, Parikh S, Hirano M. Mitochondrial', \"disease patients' perception of dietary supplements' use. Mitochondrion. 2015(24):S26-7.\", 'Mancuso M, Hirano M. Physician Guide to Mitochondrial Myopathies. National Organization', 'for Rare Disorders. 2016. Accessed on 12Mar2017. Accesible at:', 'http://nordphysicianguides.org/mitochondrial-myopathies-mm/', 'Min K, Smuder AJ, Kwon OS, Kavazis AN, Szeto HH, Powers SK. Mitochondrial-targeted', 'antioxidants protect skeletal muscle against immobilization-induced muscle atrophy. Journal of', 'Applied Physiology. 2011 Nov 1;111(5):1459-66.', 'Ng YS, Turnbull DM. Mitochondrial disease: genetics and management. Journal of neurology.', '2016 Jan 1;263(1):179-91.', 'Parikh S, Goldstein A, Koenig MK, Scaglia F, Enns GM, Saneto R, Anselm I, Cohen BH, Falk', 'MJ, Greene C, Gropman AL, Haas R, Hirano M, Morgan P, Sims K, Tarnopolsky M, Van Hove', 'JLK, Wolfe L, DiMauro S. Diagnosis and Management of Mitochondrial Disease: A consensus', 'Statement from the Mitochondrial Medicine Society. Genetics in Medicine 2015; 17(9):689-701.', 'Pfeffer G, Chinnery P. Diagnosis and treatment of mitochondria myopathies. Ann Med. 2013;', '45(1):4-16.', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '80']['SPIMM-301 Version 4.0', '15 June 2018', 'Powers SK, Hudson MB, Nelson WB, Talbert EE, Min K, Szeto HH, Kavazis AN, Smuder AJ.', 'Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm', 'weakness. Critical care medicine. 2011 Jul 1;39(7):1749-59', 'Soustek MS, Falk DJ, Mah CS, Toth MJ, Schlame M, Lewin AS, Byrne BJ. Characterization of', 'a transgenic short hairpin RNA-induced murine model of Tafazzin deficiency. Human gene', 'therapy. 2010 Dec 13;22(7):865-71.', 'Suomalainen A, Elo JM, Pietilainen KH, et al. FGF-21 as a biomarker for nuscle-manifesting', 'mitochondrial respiratory chain deficiencies: a diagnostic study. Lancet Neurol 2011;10:806-', '818.', 'Taivassalo T, Gardner JL, Taylor RW, Schaefer AM, Newman J, Barron MJ, Haller RG,', 'Turnbull DM. Endurance Training and Detraining in Mitochondrial Myopathies Due to Single', 'Large-Scale mtDNA Deletions. Brain 2006; 129:3391-3401.', 'Taivassalo T, Jensen TD, Kennaway N, DiMauro S, Vissing J, Haller RG. The spectrum of', 'exercise tolerance in mitochondrial myopathies: a study of 40 patients. Brain. 2003 Feb; 126(Pt', '2):413-23', 'Talbert EE, Smuder AJ, Min K, Kwon OS, Szeto HH, Powers SK. Immobilization-induced', 'activation of key proteolytic systems in skeletal muscles is prevented by a mitochondria-targeted', 'antioxidant. Journal of applied physiology. 2013 Aug 15;115(4):529-38.', 'Tarnopolsky M. Exercise Testing as a Diagnostic Entity in Mitochondrial Myopathies.', 'Mitochondrion 4 2004; 529-542', 'Yatsuga S, Fujita Y, Ishii A, Fukumoto Y, Arahata H, Kakuma T, Kojima T, et al. Growth', 'differentiation factor 15 as a useful biomarker for mitochondrial disorders. Ann Neurol. 2015', ';78(5):814-23.', 'Yeske P, et al. Mitochondrial Disease Clinical Trials Working Group. Challenges of Research on', 'Therapeutics in Mitochondrial Diseases. Presented at: FDA Critical Path Innovation Meeting;', 'October 19, 2015; Silver Spring, MD. Available at:', 'https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/ucm395888.htm.', 'Accessed June 27, 2017.', 'Zorov DB, Filburn CR, Klotz LO, Zweier JL, Sollott SJ. Reactive oxygen species (Ros-Induced)', 'Ros release a new phenomenon accompanying induction of the mitochondrial permeability', 'transition in cardiac myocytes. The Journal of experimental medicine. 2000 Oct 2;192(7):1001-', '14.', 'Zorov DB, Juhaszova M, Sollott SJ. Mitochondrial ROS-induced ROS release: an update and', 'review. Biochimica et Biophysica Acta (BBA)-Bioenergetics. 2006 Jun 30;1757(5):509-17.', 'Stealth BioTherapeutics Inc.', 'CONFIDENTIAL', '81']\n\n###\n\n", "completion": "END"}